<DOC>
	<DOCNO>NCT00750971</DOCNO>
	<brief_summary>While glucocorticoid immunosuppressant ameliorate manifestation SLE many patient , current therapy insufficient control disease subset patient , clinical prognosis remain poor due development vital organ failure , cumulative drug toxicity increase risk cardiovascular disease malignancy . Immunoablative chemotherapy follow autologous hematopoietic stem cell transplantation ( ASCT ) recently emerge promising experimental therapy severely affect patient , provide potential achieve treatment-free , long-term remission . The investigator postulate immunoablative therapy eliminate effectively reduces level autoreactive T B lymphocytes regeneration de novo immunity reset autoreactive immune system self-tolerant , protective immune system result prolonged treatment-free remission .</brief_summary>
	<brief_title>Autologous Stem Cell Transplantation Refractory Systemic Lupus Erythematosus ( ASSIST )</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>1 . Diagnosis SLE accord American College Rheumatology ( ACR ) classification criterion 2 . Age 18 60 year , inclusive 3 . Provision inform consent 4 . Active disease , refractory standard immunosuppressive therapy define : BILAG level A SLEDAIscore least 10 , despite treatment highdose corticosteroid pulse intravenous CYC dose 5001000mg/m2 least 6 month mycophenolate mofetil ( MMF ) dose least 2g Lupus nephritis renal biopsy perform within one year prior screen show glomerulonephritis WHO class III IV Parenchymal disease heart lung Neuropsychiatric lupus Autoimmune cytopenia OR recurrence disease activity ( defined BILAG level A SLEDAI least 10 ) within one year successful induction therapy cyclophosphamide MMF presence adequate maintenance therapy either cyclophosphamide ( least 500mg/m2 monthly ) , mycophenolate mofetil ( least 2g daily ) , azathioprine ( least 1.5mg/kg/d ) , methotrexate ( least 15mg weekly ) , cyclosporine ( least 3mg/kg/d ) patient persistent antidsDNA antibody 1 . Severe concomitant disease organ damage renal : renal insufficiency glomerular filtration rate 40ml/min cardiac : congestive heart failure , LVEF &lt; 40 % determined echocardiogram , uncontrolled arrhythmia pulmonary : mean pulmonary arterial pressure &gt; 50mmHg , DLCO &lt; 40 % predict gastrointestinal : liver cirrhosis ; SGOT , SGPT great 2 x upper limit normal , unless due active lupus 2 . Ongoing cancer history malignancy within 5 year screen 3 . Women pregnant breastfeeding use nonreliable method contraception 4 . Subjects active systemic infection 5 . Subjects history active viral infection within 6 month prior screen , know HIVinfection chronic Hepatitis B Hepatitis C 6 . History allergic reaction cyclophosphamide , GCSF ATG 7 . Use immunosuppressive agent indication SLE 8 . Any comorbidity opinion investigator would jeopardize ability subject tolerate therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ASSIST</keyword>
	<keyword>SLE</keyword>
	<keyword>Stem Cell Transplantation</keyword>
	<keyword>Tolerance</keyword>
</DOC>